Want to see OLMA full AI Analyst Report?
Olema Pharmaceuticals (OLMA) Stock Forecast & Price Target
1,022 Followers
OLMA Analyst Ratings
Strong Buy
9Buy0Hold0Sell
Based on 9 analysts giving stock ratings to Olema Pharmaceuticals in the past 3 months
OLMA Stock 12 Month Forecast
Average Price Target
$33.43▲(394.51% Upside)Based on 9 Wall Street analysts offering 12 month price targets for Olema Pharmaceuticals in the last 3 months. The average price target is $33.43 with a high forecast of $59.00 and a low forecast of $16.00. The average price target represents a 394.51% change from the last price of $6.76.
Past 12 Months12 Month ForecastJan2026Oct2026
High$59.00
Average$33.43
Low$16.00
Highest Price TargetHighest$59.00Average Price Target$33.43Lowest Price TargetLowest$16.00
Detailed List of Analyst Forecasts
Analyst Type
Ranks
Analyst Rating
Upside/ Downside
Action
| Price Target | Follow | Article | ||||||
|---|---|---|---|---|---|---|---|---|
 Unknown AnalystNot Ranked | Guggenheim | $35 | buy | 417.75%Upside | Initiated | 11/04/26 | ||
| Emily Bodnar | H.C. Wainwright | $36 | buy | 432.54%Upside | Reiterated | 09/21/26 | ||
| Sam Slutsky | LifeSci Capital | $16 | buy | 136.69%Upside | Reiterated | 09/19/26 | ||
| Anupam Rama | J.P. Morgan | ― | buy | ― | Reiterated | 09/14/26 | ||
| Laura Prendergast | Stifel Nicolaus | $48→$30 | buy | 343.79%Upside | Reiterated | 09/14/26 | ||
| Richard Law CFA | Goldman Sachs | $20→$18 | buy | 166.27%Upside | Reiterated | 09/14/26 | ||
| Yigal Nochomovitz | Citi | $59 | buy | 772.78%Upside | Reiterated | 09/13/26 | ||
| Kelsey Goodwin | Piper Sandler | $40 | buy | 491.72%Upside | Reiterated | 08/20/26 | ||
| Tyler Van Buren | TD Cowen | ― | buy | ― | Reiterated | 08/10/26 | ||
| Michael Yee | UBS | $45 | buy | 565.68%Upside | Reiterated | 06/02/26 | ||
| Kalpit Patel | Wolfe Research | ― | hold | ― | Initiated | 03/26/26 | ||
| Dennis Ding | Jefferies | $43→$40 | buy | 491.72%Upside | Initiated | 03/19/26 |
| Rating | Follow | Article | |||
|---|---|---|---|---|---|
| Unknown AnalystGuggenheimNot Ranked | BuyInitiated$35 | 11/04/26 | 417.75%Upside | ||
| Emily BodnarH.C. Wainwright | BuyReiterated$36 | 09/21/26 | 432.54%Upside | ||
| Sam SlutskyLifeSci Capital | BuyReiterated$16 | 09/19/26 | 136.69%Upside | ||
| Anupam RamaJ.P. Morgan | BuyReiterated | 09/14/26 | ― | ||
| Laura PrendergastStifel Nicolaus | BuyReiterated$48→$30 | 09/14/26 | 343.79%Upside | ||
| Richard Law CFAGoldman Sachs | BuyReiterated$20→$18 | 09/14/26 | 166.27%Upside | ||
| Yigal NochomovitzCiti | BuyReiterated$59 | 09/13/26 | 772.78%Upside | ||
| Kelsey GoodwinPiper Sandler | BuyReiterated$40 | 08/20/26 | 491.72%Upside | ||
| Tyler Van BurenTD Cowen | BuyReiterated | 08/10/26 | ― | ||
| Michael YeeUBS | BuyReiterated$45 | 06/02/26 | 565.68%Upside | ||
| Kalpit PatelWolfe Research | HoldInitiated | 03/26/26 | ― | ||
| Dennis DingJefferies | BuyInitiated$43→$40 | 03/19/26 | 491.72%Upside |
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Best Analysts Covering Olema Pharmaceuticals
3 Months
Success Rate11/19 ratings generated profit
58%
Average Return
+5.96%
Copying Michael Yee's trades and holding each position for 3 Months would result in 57.89% of your transactions generating a profit, with an average return of +5.96% per trade.
1 Year
Success Rate10/28 ratings generated profit
36%
Average Return
+49.72%
Copying Emily Bodnar's trades and holding each position for 1 Year would result in 35.71% of your transactions generating a profit, with an average return of +49.72% per trade.
2 Years
Success Rate9/19 ratings generated profit
47%
Average Return
+34.34%
Copying Michael Yee's trades and holding each position for 2 Years would result in 47.37% of your transactions generating a profit, with an average return of +34.34% per trade.
OLMA Analyst Recommendation Trends
| Rating | Jun 26 | Jul 26 | Aug 26 | Sep 26 | Oct 26 |
|---|---|---|---|---|---|
| Strong Buy | 17 | 15 | 17 | 15 | 8 |
| Buy | 3 | 3 | 3 | 3 | 1 |
| Hold | 1 | 1 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 |
| total | 21 | 19 | 20 | 18 | 9 |
In the current month, OLMA has received 9 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. OLMA average Analyst price target in the past 3 months is 33.43.
OLMA Financial Forecast
High$-0.50
Consensus$-0.64
Low$-0.73
OLMA Earnings Forecast
Next quarter’s earnings estimate for OLMA is -$0.64 with a range of -$0.73 to -$0.50. The previous quarter’s EPS was -$0.61. Its overall industry beat the EPS estimate 57.80% of the time in the past 12 months.
High$0.00
Consensus$0.00
Low$0.00
OLMA Sales Forecast
Next quarter’s sales forecast for OLMA is $0 with a range of $0 to $0. The previous quarter’s sales results were $0. Its overall industry beat sales estimates 50.04% of the time in the past 12 months.
OLMA Stock Forecast FAQ
What is OLMA’s average 12-month price target, according to analysts?
Based on analyst ratings, Olema Pharmaceuticals’s 12-month average price target is $33.43.
What is OLMA’s upside potential, based on the analysts’ average price target?
Olema Pharmaceuticals has 394.51% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is OLMA a Buy, Sell or Hold?
Olema Pharmaceuticals has a consensus rating of Strong Buy which is based on 9 buy ratings, 0 hold ratings and 0 sell ratings.
What is Olema Pharmaceuticals’s price target?
The average price target for Olema Pharmaceuticals is $33.43. This is based on 9 12-month price targets, issued in the past 3 months. The highest analyst price target is $59.00, the lowest forecast is $16.00. The average price target represents a 394.51% increase from the current price of $6.76.
What do analysts say about Olema Pharmaceuticals?
Olema Pharmaceuticals’s analyst rating consensus is a Strong Buy. This is based on the ratings of 9 Wall Street analysts.
How can I buy shares of OLMA?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
